

Acquisition of Kinetic Concepts Inc's (KCI) Therapeutic Support Systems (TSS) business

15 August, 2012

Transaction overview

- Getinge has signed a definitive agreement with US-based Kinetic Concepts Inc. to acquire its Therapeutic Support Systems (TSS) business for an enterprise value of USD 275 million.
- The acquisition of TSS takes the form of a carve-out whereby Getinge will purchase all assets and intellectual property associated with the TSS business.
- 2011 EV/EBITDA multiple of 5.7x
- 2011 EV/EBITDA multiple of 5.1x including tax assets of USD 30 million








Strategic rationale – TSS acquisition

Geographically, highly complementary – TSS and Getinge
 Extended Care's combined business will create a global market position of No. 1.



- Customer segment significant potential for synergies and increased customer value.
 - TSS strong in Critical and Bariatric Care
 - Both TSS and Extended Care strong in Wound Care



- TSS strength is in Low Air Loss (LAL) technology while Extended Care is more advanced in Alternating Pressure (AP)





About TSS and the market

- Overview: One of three business divisions in the global medical device company KCI, focused on sustained market leadership in Wound Care, Bariatric Care and Critical Care.
- Location: San Antonio, Texas, USA
- Own sales organizations in: the US, Canada, Germany, Austria, Italy, Switzerland, the UK and France
- Sales breakdown: 60% in US and 40% in ROW
- Revenues: ~ USD 247 million in 2011
- Product portfolio: Therapeutic beds, mattress replacements, overlays and patient mobility devices
- No of employees: ~1,300 globally



About TSS and the market - contd.

Three divisions with total revenue of USD 247 million in 2011

KCI Therapeutic Support Systems

Wound care 2011A Revenue: \$155 million (63%)

Bariatric care 2011A Revenue: \$51 million (21%) Critical care 2011A Revenue: \$34 million (14%)



Develops and manufactures support surfaces, overlays, therapeutic beds and mattress replacement systems that help facilities meet their woundhealing goals and manage the complications and expenses associated with pressure ulcers



Develops and manufactures solutions that help treat and prevent pressure ulcers to enable caregivers to care for obese patients in a safe and dignified manner in all care settings





Develops and manufactures critical care products, often used in the intensive care unit ("ICU"), which are designed to address pulmonary complications associated with immobility


About TSS and the market - contd.

Therapeutic surfaces for treatment and prevention of pressure ulcers represents a market with stable growth and favourable demographic trends

- Global market valued at USD 1.5 billion.
- Stable global market growth of approximately 5-7% annually.
 - US market growth approximately 2-3%
- Strong and well-known brands
 - Globally, TSS is one of the most well-known brands in wound care
- Favourable demographic trends (Bariatrics)
- Pressure ulcers a preventable condition with high associated costs
 (> USD 50,000 per case to treat)







Synergies and financial impact

- The combination of TSS's and Extended Care's existing business is expected to create operational synergies in sales, distribution operations, manufacturing and headquarter functions.
- The complementary nature of the two product portfolios is expected to generate revenue synergies and increased customer value.
- The transaction will contribute to Getinge's pre-tax profit from 2013 onwards (including restructuring costs, financing costs and amortisation of acquired surplus value).
- Transaction and restructuring costs will amount to USD 35 million, whereas
 USD 25 million will be charged to Getinge's Q4 result this year.
- The acquisition is subject to approval by relevant Competition Authorities in several markets and is expected to be finalised by the end of Q4 2012.
- The transaction is being financed through a bridge loan.